Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: The COSMETIC study

Clinical Endocrinology

Volumn 77, Issue 2, 2012, Pages 215-223

  Lim, Soo ^a,b   An, Jee Hyun ^b   Shin, Hayley ^c   Khang, Ah Reum ^b   Lee, Yenna ^a,b   Ahn, Hwa Young ^a,b   Yoon, Ji Won ^a,b   Kang, Seon Mee ^a,b   Choi, Sung Hee ^a,b   Cho, Young Min ^b   Park, Kyong Soo ^b   Jang, Hak Chul ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; CREATININE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SITAGLIPTIN; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; GROUPS BY AGE AND SEX; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VOMITING;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84863705544     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04240.x     Document Type: Article

References (39)

1. Nauck, M.A., Meininger, G., Sheng, D., et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity & Metabolism, 9, 194-205.
2. Nonaka, K., Kakikawa, T., Sato, A., et al. (2008) Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice, 79, 291-298.
3. Aschner, P., Katzeff, H.L., Guo, H., et al. (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 12, 252-261.
4. Xu, L., Man, C.D., Charbonnel, B., et al. (2008) Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes, Obesity & Metabolism, 10, 1212-1220.
5. Brazg, R., Xu, L., Dalla, M.C., et al. (2007) Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 9, 186-193.
6. Herman, G.A., Bergman, A., Stevens, C., et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 91, 4612-4619.
7. Hinke, S.A., Kuhn-Wache, K., Hoffmann, T., et al. (2002) Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochemical and Biophysical Research Communications, 291, 1302-1308.
8. Yasuda, N., Inoue, T., Nagakura, T., et al. (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochemical and Biophysical Research Communications, 298, 779-784.
9. Mannucci, E., Ognibene, A., Cremasco, F., et al. (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care, 24, 489-494.
10. Goldstein, B.J., Feinglos, M.N., Lunceford, J.K., et al. (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care, 30, 1979-1987.
11. Williams-Herman, D., Johnson, J., Teng, R., et al. (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 12, 442-451.
12. Rosenstock, J., Brazg, R., Andryuk, P.J., et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics, 28, 1556-1568.
13. Kim, S.A., Shim, W.H., Lee, E.H., et al. (2011) Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes & Metabolism Journal, 35, 159-165.
14. Kim, W.J., Park, C.Y., Jeong, E.H., et al. (2011) Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month duration. Diabetes & Metabolism Journal, 35, 290-297.
15. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
16. Seltzer, H.S., Allen, E.W., Herron Jr, A.L., et al. (1967) Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. Journal of Clinical Investigation, 46, 323-335.
17. Ni, M.C., Rodgers, A., Pan, W.H., et al. (2004) Body mass index and cardiovascular disease in the Asia-Pacific region: an overview of 33 cohorts involving 310 000 participants. International Journal of Epidemiology, 33, 751-758.
18. Sherifali, D., Nerenberg, K., Pullenayegum, E., et al. (2010) The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care, 33, 1859-1864.
19. Pratley, R.E., Schweizer, A., Rosenstock, J., et al. (2008) Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity & Metabolism, 10, 931-938.
20. Michishita, R., Shono, N., Kasahara, T., et al. (2008) Effects of low intensity exercise therapy on early phase insulin secretion in overweight subjects with impaired glucose tolerance and type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 82, 291-297.
21. King, G.L., Kunisaki, M., Nishio, Y., et al. (1996) Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes, 45 (Suppl 3), S105-S108.
22. Giugliano, D., Ceriello, A., &, Paolisso, G., (1996) Oxidative stress and diabetic vascular complications. Diabetes Care, 19, 257-267.
23. Miyazaki, Y., Kawano, H., Yoshida, T., et al. (2007) Pancreatic B-cell function is altered by oxidative stress induced by acute hyperglycaemia. Diabetic Medicine, 24, 154-160.
24. van Raalte, D.H., &, Diamant, M., (2011) Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? Diabetes Research and Clinical Practice, 93 (Suppl 1), S37-S46.
25. Maida, A., Lamont, B.J., Cao, X., et al. (2011) Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia, 54, 339-349.
26. Cho, Y.M., &, Kieffer, T.J., (2010) New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia, 54, 219-222.
27. Hermans, M.P., Levy, J.C., Morris, R.J., et al. (1999) Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes, 48, 1779-1786.
28. Emoto, M., Nishizawa, Y., Maekawa, K., et al. (1999) Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care, 22, 818-822.
29. Hosker, J.P., Matthews, D.R., Rudenski, A.S., et al. (1985) Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia, 28, 401-411.
30. Simonis-Bik, A.M., Boomsma, D.I., Dekker, J.M., et al. (2011) The heritability of beta cell function parameters in a mixed meal test design. Diabetologia, 54, 1043-1051.
31. Elder, D.A., Woo, J.G., &, D'Alessio, D.A., (2010) Impaired beta-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes. Pediatric Diabetes, 11, 314-321.
32. Tanabe, N., Saito, K., Yamada, Y., et al. (2009) Risk assessment by post-challenge plasma glucose, insulin response ratio, and other indices of insulin resistance and/or secretion for predicting the development of type 2 diabetes. Internal Medicine, 48, 401-409.
33. Mari, A., Tura, A., Pacini, G., et al. (2008) Relationships between insulin secretion after intravenous and oral glucose administration in subjects with glucose tolerance ranging from normal to overt diabetes. Diabetic Medicine, 25, 671-677.
34. Faerch, K., Vaag, A., Holst, J.J., et al. (2008) Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia, 51, 853-861.
35. Alssema, M., Schindhelm, R.K., Rijkelijkhuizen, J.M., et al. (2009) Meal composition affects insulin secretion in women with type 2 diabetes: a comparison with healthy controls. The Hoorn prandial study. European Journal of Clinical Nutrition, 63, 398-404.
36. Cretti, A., Lehtovirta, M., Bonora, E., et al. (2001) Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. European Journal of Clinical Investigation, 31, 405-416.
37. Lenhard, J.M., Croom, D.K., &, Minnick, D.T., (2004) Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochemical and Biophysical Research Communications, 324, 92-97.
38. Lindsay, J.R., Duffy, N.A., McKillop, A.M., et al. (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabetic Medicine, 22, 654-657.
39. Charbonnel, B., Karasik, A., Liu, J., et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 29, 2638-2643.